The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD
Open accessAbstract
Reduced GFR in patients with CKD causes systemic accumulation of uremic toxins, which has been correlated with disease progression and increased morbidity. The orally administered spherical carbon adsorbent AST-120 reduces systemic toxin absorption through gastrointestinal sequestration, which may slow disease progression in these patients. The multinational, randomized, double-blind, placebo-controlled Evaluating Prevention of Progression in CKD (EPPIC)-1 and EPPIC-2 trials evaluated the effects of AST-120 on the progression of CKD when added to standard therapy. We randomly assigned 2035 adults with moderate to severe disease (serum creatinine at screening, 2.0-5.0 mg/dl for men and 1.5-5.0 mg/dl for women) to receive either placebo or AST-120 (9 g/d). The primary end point was a composite of dialysis initiation, kidney transplantation, and serum creatinine doubling. Each trial continued until accrual of 291 primary end points. The time to primary end point was similar between the AST-120 and the placebo groups in both trials (EPPIC-1: hazard ratio, 1.03; 95% confidence interval, 0.84 to 1.27; P=0.78) (EPPIC-2: hazard ratio, 0.91; 95% confidence interval, 0.74 to 1.12; P=0.37); a pooled analysis of both trials showed similar results. The estimated median time to primary end points for the placebo groups was 124 weeks for power calculations, but actual times were 189.0 and 170.3 weeks for EPPIC-1 and EPPIC-2, respectively. Thus, disease progression was more gradual than expected in the trial populations. In conclusion, the benefit of adding AST-120 to standard therapy in patients with moderate to severe CKD is not supported by these data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationSontrop, J. M., Dixon, S. N., Garg, A. X., Buendia-Jimenez, I., Dohein, O., Huang, S.-H. S., & Clark, W. F. (2013) · American Journal of Nephrology · doi:10.1159/000350377 · Cited by 5,871
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Review on uremic toxins: Classification, concentration, and interindividual variability
Vanholder, R., For the European Uremic Toxin Work Group (EUTox), De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., Clark, W., Cohen, G., De Deyn, P. P., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00924.x · Cited by 1,720
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
(2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.003 · Cited by 1,245
Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument
Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., & Carter, W. B. (1994) · Quality of Life Research · doi:10.1007/bf00451725 · Cited by 1,193
Matsushita, K., Mahmoodi, B. K., Woodward, M., Emberson, J. R., Jafar, T. H., Jee, S. H., Polkinghorne, K. R., Shankar, A., Smith, D. H., Tonelli, M., et al. (2012) · JAMA · doi:10.1001/jama.2012.3954 · Cited by 988
Agodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., & Massy, Z. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03980609 · Cited by 929
Early recognition and prevention of chronic kidney disease
James, M. T., Hemmelgarn, B. R., & Tonelli, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62004-3 · Cited by 606
Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease
Wu, I.-W., Hsu, K.-H., Lee, C.-C., Sun, C.-Y., Hsu, H.-J., Tsai, C.-J., Tzen, C.-Y., Wang, Y.-C., Lin, C.-Y., & Wu, M.-S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq580 · Cited by 510
(2004) · PubMed · Cited by 502
Liabeuf, S., Barreto, D. V., Barreto, F. C., Meert, N., Glorieux, G., Schepers, E., Temmar, M., Choukroun, G., Vanholder, R., Massy, Z. A., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp592 · Cited by 431
p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease
Meijers, B. K. I., Claes, K., Bammens, B., de Loor, H., Viaene, L., Verbeke, K., Kuypers, D., Vanrenterghem, Y., & Evenepoel, P. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07971109 · Cited by 316
Schulman, G., Agarwal, R., Acharya, M., Berl, T., Blumenthal, S., & Kopyt, N. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.12.036 · Cited by 200
Self-citationAldosterone antagonists for preventing the progression of chronic kidney disease
Bolignano, D., Palmer, S. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub3 · Cited by 189
Cardiorenal Syndrome: The Emerging Role of Protein-Bound Uremic Toxins
Lekawanvijit, S., Kompa, A. R., Wang, B. H., Kelly, D. J., & Krum, H. (2012) · Circulation Research · doi:10.1161/circresaha.112.278457 · Cited by 183
Aldosterone antagonists for preventing the progression of chronic kidney disease
Navaneethan, S. D., Nigwekar, S. U., & Strippoli, G. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004 · Cited by 166
Shoji, T., Wada, A., Inoue, K., Hayashi, D., Tomida, K., Furumatsu, Y., Kaneko, T., Okada, N., Fukuhara, Y., Imai, E., et al. (2006) · Nephron Clinical Practice · doi:10.1159/000097985 · Cited by 75
Konishi, K., Nakano, S., Tsuda, S.-I., Nakagawa, A., Kigoshi, T., & Koya, D. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.024 · Cited by 72
Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Suzuki, T., Ueda, Y., & Yamagishi, S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.023 · Cited by 53
Hatakeyama, S., Yamamoto, H., Okamoto, A., Imanishi, K., Tokui, N., Okamoto, T., Suzuki, Y., Sugiyama, N., Imai, A., Kudo, S., et al. (2012) · International Journal of Nephrology · doi:10.1155/2012/376128 · Cited by 47
Marier, J., Lee, J. D., Kambhampati, S. R. P., et al. (2006) · American Journal of Nephrology · doi:10.1159/000092242 · Cited by 20
Yorioka, N., Kiribayashi, K., Naito, T., et al. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.2.213 · Cited by 17
Cited by
Nutritional Management of Chronic Kidney Disease
Kalantar-Zadeh, K., & Fouque, D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1700312 · Cited by 636
The Gut as a Source of Inflammation in Chronic Kidney Disease
Lau, W. L., Kalantar-Zadeh, K., & Vaziri, N. D. (2015) · Nephron · doi:10.1159/000381990 · Cited by 461
Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis, P., Dekker, F. W., Fliser, D., Fouque, D., Heine, G. H., Jager, K. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.52 · Cited by 444
Gryp, T., Vanholder, R., Vaneechoutte, M., & Glorieux, G. (2017) · Toxins · doi:10.3390/toxins9020052 · Cited by 417
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target
Ramezani, A., Massy, Z. A., Meijers, B., Evenepoel, P., Vanholder, R., & Raj, D. S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.027 · Cited by 394
Metadata
- Authors
- Schulman, G., Berl, T., Beck, G. J., Remuzzi, G., Ritz, E., Arita, K., Kato, A., & Shimizu, M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2015-07
- Volume
- 26
- Issue
- 7
- Pages
- 1732-1746
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2167578151
- Cited by
- 282
- References
- 35
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.